Health technology and data science firm IQVIA (NYSE: IQV) is launching its fourth “IQVIA Prime” site in the UK, together with the National Institute for Health Research (NIHR), Britain’s state-run clinical research fund.
The site, which will employ more than 50 newly-recruited high-skilled staff, will focus on the delivery of clinical research across the North of England, supporting clinical trials and real-world evidence studies in this area.
IQVIA currently conducts more than 20% of all commercial clinical trials in the country’s national healthcare provider, the National Health Service (NHS).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze